Kelonia Therapeutics presented in‑vivo CAR‑T data that showed efficacy signals in multiple myeloma models and early clinical reports, bolstering confidence in intramuscular or systemic delivery approaches that engineer patient T cells without ex vivo manipulation. The Kelonia readouts, together with other early in‑vivo CAR‑T updates at ASH, demonstrate growing clinical traction for simpler, off‑the‑shelf or in‑vivo modalities. Investors and developers view in‑vivo CAR‑T as a potential route to dramatically lower manufacturing complexity and cost versus autologous CAR‑T. Data remain early; regulators and payers will scrutinize durability, safety and patient selection as the field moves toward broader trials. Sources: ASH meeting coverage and company presentations.